The Business Research Company’s report on the Chemotherapy-Induced Anemia Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the chemotherapy-induced anemia market in recent years?
The high prevalence of cancer and anemia is expected to propel the growth of the chemotherapy-induced anemia market going forward. Cancer is a disease where somebody’s cells grow out of control and spread to other body regions. In cancer patients receiving aggressive chemotherapy, whether with or without radiation therapy, cancer and chemotherapy-induced anemia (CIA) are frequent occurrences. The medication stimulates the production of red blood cells in the bone marrow and can be used to treat chemotherapy-induced anemia. For instance, in 2023, according to Cancer Research UK, a UK-based independent cancer research organization, the incidence of head and neck cancer in the UK is projected to rise by 3% between 2023 and 2025, while deaths due to head and neck cancers are expected to increase by 12% between 2023 and 2025. Therefore, the high prevalence of cancer and anemia drives the growth of the chemotherapy-induced anemia market.
Access Your Free Sample of the Global Chemotherapy-Induced Anemia Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12513&type=smp
What is the projected market size of the chemotherapy-induced anemia industry, and how is it expected to grow?
The chemotherapy-induced anemia market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increased prevalence of cancer and chemotherapy treatments, aging population leading to higher cancer incidence, expansion of chemotherapy drugs and regimens, improvement in overall cancer survival rates, awareness and diagnosis of anemia as a side effect
The chemotherapy-induced anemia market size is expected to see strong growth in the next few years. It will grow to $3.81 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to development of supportive care in oncology, rise in healthcare expenditure and infrastructure, personalized medicine and targeted cancer therapies, integration of biomarker-driven treatment approaches, increasing focus on early detection and intervention, integration of digital health technologies in patient management. Major trends in the forecast period include innovation of novel chemotherapy agents, integration of ml, advancements in cancer research and treatment protocols, integration of ai, collaboration between pharmaceutical companies and healthcare providers.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12513&type=smp
Who are the key players driving competition in the chemotherapy-induced anemia market?
Major companies operating in the chemotherapy-induced anemia market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Hospira Inc., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., 3SBio Group, FibroGen Inc., Karger AG, Avesthagen Ltd., Blausen Medical Communications Inc., Aileron Therapeutics Inc.
What key trends are expected to drive the chemotherapy induced peripheral neuropathy treatment market during the forecast period?
Major companies operating in the chemotherapy-induced anemia market are focused on developing innovative products such as biosimilars to enhance treatment efficacy and reduce costs. Biosimilars are biologic medical products that are highly similar to an already approved reference biologic drug, with no significant differences in safety, purity, or effectiveness. They are designed to offer more affordable alternatives to expensive biologic treatments while maintaining comparable therapeutic outcomes. For instance, in November 2022, Amneal Pharmaceuticals, Inc., a US-based pharmaceutical company, launched RELEUKO (filgrastim-ayow). This product references Neupogen® and is primarily indicated for the treatment of neutropenia, a conditio n often experienced by patients undergoing chemotherapy. offers significant benefits for patients undergoing cancer treatment. It is primarily indicated to decrease the incidence of infections associated with febrile neutropenia in patients receiving myelosuppressive chemotherapy, thereby enhancing their safety and recovery. Additionally, RELEUKO® aids in reducing the time to neutrophil recovery and the duration of fever following chemotherapy for acute myeloid leukemia, and it helps mitigate the complications of neutropenia in patients undergoing bone marrow transplantation.
Which key geographies are driving the growth of the chemotherapy-induced anemia market?
North America was the largest region in the chemotherapy-induced anemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
What are the key segments driving growth in the chemotherapy-induced anemia market?
The chemotherapy-induced anemia market covered in this report is segmented –
1) By Anemia: Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia
2) By Treatment Type: RBC (Red Blood Cells) Transfusion, Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation
3) By End-User: Hospitals, Ambulatory Surgical Centers, Multispecialty Clinics, Cancer Research Centers, Cancer Rehabilitation Centers
Subsegments:
1) By Mild Anemia: Hemoglobin Levels 10-12 g/dL, Symptomatic Treatments
2) By Moderate Anemia: Hemoglobin Levels 8-10 g/dL, Erythropoiesis-stimulating Agents (ESAs), Blood Transfusion Management
3) By Severe Anemia: Hemoglobin Levels 6.5-8 g/dL, Intensive ESA Treatments, Frequent Blood Transfusions
4) By Life-Threatening Anemia: Hemoglobin Levels Below 6.5 g/dL, Emergency interventions, Critical Care And Monitoring
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12513
What defines the structure and scope of the chemotherapy-induced anemia market?
Chemotherapy-Induced Anemia refers to a decrease in red blood cells caused by chemotherapy treatments, leading to fatigue, weakness, and other symptoms. It is used to manage the side effects of cancer treatment, helping to improve patients’ quality of life. Addressing this condition often involves erythropoiesis-stimulating agents or blood transfusions.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
